RE-VANA THERAPEUTICS

Re-Vana Therapeutics is a pioneering ocular drug delivery and therapeutic company focused on developing the world's first sustained-release large molecule biologics to treat serious eye diseases. Our innovative platform technologies, EyeLief®, EyeLief SD™, and OcuLief®, enable the efficient delivery of biologics and small molecules, expanding global treatment opportunities. With a multi-billion-dollar market segment, our non-surgical approach offers a significant advantage over traditional treatments. Furthermore, Re-Vana has potential market expansion opportunities beyond the eye, positioning us for long-term growth and success... Re-Vana Therapeutics has created a set of exceptional photo-crosslinked biodegradable technologies, including EyeLief, EyeLief SD, and OcuLief, that can deliver biologics and small drugs to the eye for an extended period of 6 months to 2 years. EyeLief and EyeLief-SD undergo photo-crosslinking before being inserted into the eye. In contrast, OcuLief is a..